SELECT-GCA: Upadacitinib in Giant Cell Arteritis Save
Dr. Mike Putman reports on abstract 0770, Efficacy and Safety of Upadacitinib in Patients with Giant Cell Arteritis (SELECT-GCA): A Double-Blind, Randomized Controlled Phase 3 Trial, presented at the 2024 ACR Convergence meeting in Washington, DC.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.